×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ITCI – intra-cellular therapies inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ITCI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
08:20 am
itci
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]
11/19
08:00 am
itci
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Low
Report
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
11/7
08:00 am
itci
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Low
Report
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
11/6
09:02 am
itci
Intra-Cellular bolsters Caplyta data with another Phase III win [Yahoo! Finance]
Low
Report
Intra-Cellular bolsters Caplyta data with another Phase III win [Yahoo! Finance]
11/5
07:00 am
itci
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
Low
Report
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
11/4
09:31 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at JPMorgan Chase & Co. from $81.00 to $89.00. They now have an "overweight" rating on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at JPMorgan Chase & Co. from $81.00 to $89.00. They now have an "overweight" rating on the stock.
11/2
09:53 am
itci
Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results [Yahoo! Finance]
Low
Report
Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results [Yahoo! Finance]
11/1
08:53 am
itci
Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Low
Report
Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2024
07:30 am
ITCI
intra-cellular therapies inc.
MISS
Report
9.6%
intra-cellular therapies inc.
8/7/2024
07:30 am
ITCI
intra-cellular therapies inc.
BEAT
Report
-5.8%
intra-cellular therapies inc.
5/7/2024
07:30 am
ITCI
intra-cellular therapies inc.
BEAT
Report
-2.9%
intra-cellular therapies inc.
2/22/2024
07:30 am
ITCI
intra-cellular therapies inc.
BEAT
Report
-4.1%
intra-cellular therapies inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
06:01 pm
itci
Form 4 Intra-Cellular Therapies For: Nov 12 Filed by: Halstead Michael
Medium
Report
Form 4 Intra-Cellular Therapies For: Nov 12 Filed by: Halstead Michael
11/12
04:28 pm
itci
Form 144 Intra-Cellular Therapies Filed by: Halstead Michael
Low
Report
Form 144 Intra-Cellular Therapies Filed by: Halstead Michael
11/12
10:33 am
itci
Form SC 13G/A Intra-Cellular Therapies Filed by: FMR LLC
Low
Report
Form SC 13G/A Intra-Cellular Therapies Filed by: FMR LLC
11/8
05:32 pm
itci
Form SC 13G/A Intra-Cellular Therapies Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A Intra-Cellular Therapies Filed by: BlackRock, Inc.
11/5
07:11 am
itci
Form 8-K Intra-Cellular Therapies For: Nov 05
Low
Report
Form 8-K Intra-Cellular Therapies For: Nov 05
10/30
07:54 am
itci
Form 10-Q Intra-Cellular Therapies For: Sep 30
High
Report
Form 10-Q Intra-Cellular Therapies For: Sep 30
10/30
07:45 am
itci
Form 8-K Intra-Cellular Therapies For: Oct 30
High
Report
Form 8-K Intra-Cellular Therapies For: Oct 30
10/24
02:03 pm
itci
Form SC 13G/A Intra-Cellular Therapies Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A Intra-Cellular Therapies Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/23
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
194.7%
6/13 Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults 14.3%
6/14 Form DEFA14A Intra-Cellular Therapies 13.1%
7/8 Intra-Cellular drug fails bipolar depression study; shares fall 14% [Reuters (UK)] 12.8%
4/7 Intra-Cellular Therapies: This Small Cap Biotech Will Not Be Small For Long [Seeking Alpha] 11.4%
8/5 Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA 8.5%
4/29 Intra-Cellular Therapies to Host First Quarter 2020 Financial Results Conference Call and Webcast 7.4%
9/7 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.4%
1/6 Form S-3ASR Intra-Cellular Therapies 6.9%
10/15 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 5.8%
6/13 Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults 14.3%
6/14 Form DEFA14A Intra-Cellular Therapies 13.1%
7/8 Intra-Cellular drug fails bipolar depression study; shares fall 14% [Reuters (UK)] 12.8%
4/7 Intra-Cellular Therapies: This Small Cap Biotech Will Not Be Small For Long [Seeking Alpha] 11.4%
8/5 Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA 8.5%
4/29 Intra-Cellular Therapies to Host First Quarter 2020 Financial Results Conference Call and Webcast 7.4%
9/7 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.4%
1/6 Form S-3ASR Intra-Cellular Therapies 6.9%
10/15 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 5.8%
TOP News Decliners
7/8
Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression
-16.4%
12/23 Intra-Cellular drug approval augurs well for CNS stocks, Stifel says [Seeking Alpha] -14.1%
3/6 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -13.4%
1/7 Intra-Cellular Therapies Prices Public Offering of Common Stock -12.7%
3/18 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -8.7%
6/19 Form 4/A Intra-Cellular Therapies For: Nov 22 Filed by: Alafi Christopher D -8.4%
7/24 Form 8-K Intra-Cellular Therapies For: Jul 23 -8.2%
9/12 Form 424B3 Intra-Cellular Therapies -7.6%
2/21 Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.9%
1/8 Form 4 Intra-Cellular Therapies For: Jan 06 Filed by: Hineline Lawrence J. -5.1%
12/23 Intra-Cellular drug approval augurs well for CNS stocks, Stifel says [Seeking Alpha] -14.1%
3/6 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -13.4%
1/7 Intra-Cellular Therapies Prices Public Offering of Common Stock -12.7%
3/18 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -8.7%
6/19 Form 4/A Intra-Cellular Therapies For: Nov 22 Filed by: Alafi Christopher D -8.4%
7/24 Form 8-K Intra-Cellular Therapies For: Jul 23 -8.2%
9/12 Form 424B3 Intra-Cellular Therapies -7.6%
2/21 Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.9%
1/8 Form 4 Intra-Cellular Therapies For: Jan 06 Filed by: Hineline Lawrence J. -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: